Utility of Insulin Resistance in Estimating Cardiovascular Risk in Subjects with Type 1 Diabetes According to the Scores of the Steno Type 1 Risk Engine.
cardiovascular risk
estimated insulin sensitivity
insulin resistance
steno type 1 risk engine
type 1 diabetes
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
11 Jul 2020
11 Jul 2020
Historique:
received:
05
06
2020
revised:
06
07
2020
accepted:
08
07
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
16
7
2020
Statut:
epublish
Résumé
We sought to assess the potential of insulin resistance (IR) for estimating cardiovascular disease (CVD) risk in adults with type 1 diabetes (T1DM) according to the scores of the Steno Type 1 Risk Engine (ST1RE). A total of 179 adults with T1DM (50.8% men, age 41.2 ± 13.1 years, duration of T1DM 16 (12-23) years) without established CVD were evaluated. IR was assessed by the estimation of insulin sensitivity (eIS) using two validated prediction equations: the estimated insulin sensitivity developed from the Pittsburgh Epidemiology of Diabetes Complications Study (eIS-EDC) and the estimated insulin sensitivity developed from Coronary Artery Calcification in T1DM Study (eIS-CACTI) ST1RE was used to estimate 10-year CVD risk and to classify subjects into three groups according to their risk: low (<10%; Both eIS-EDC and eIS-CACTI correlated negatively with ST1RE scores (eIS-EDC: r = -0.636, eIS negatively correlates with the score of CVD risk in the ST1RE. Two cut-off points of eIS are reported with potential utility in clinical practice for detecting adults with T1DM with the highest CVD risk.
Sections du résumé
BACKGROUND
BACKGROUND
We sought to assess the potential of insulin resistance (IR) for estimating cardiovascular disease (CVD) risk in adults with type 1 diabetes (T1DM) according to the scores of the Steno Type 1 Risk Engine (ST1RE).
METHODS
METHODS
A total of 179 adults with T1DM (50.8% men, age 41.2 ± 13.1 years, duration of T1DM 16 (12-23) years) without established CVD were evaluated. IR was assessed by the estimation of insulin sensitivity (eIS) using two validated prediction equations: the estimated insulin sensitivity developed from the Pittsburgh Epidemiology of Diabetes Complications Study (eIS-EDC) and the estimated insulin sensitivity developed from Coronary Artery Calcification in T1DM Study (eIS-CACTI) ST1RE was used to estimate 10-year CVD risk and to classify subjects into three groups according to their risk: low (<10%;
RESULTS
RESULTS
Both eIS-EDC and eIS-CACTI correlated negatively with ST1RE scores (eIS-EDC: r = -0.636,
CONCLUSIONS
CONCLUSIONS
eIS negatively correlates with the score of CVD risk in the ST1RE. Two cut-off points of eIS are reported with potential utility in clinical practice for detecting adults with T1DM with the highest CVD risk.
Identifiants
pubmed: 32664522
pii: jcm9072192
doi: 10.3390/jcm9072192
pmc: PMC7409001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI09/01360 PI12/00954 and PI15/00567
Organisme : Instituto de Salud Carlos III
ID : CB07708/0012
Organisme : Instituto de Salud Carlos III
ID : CP10/00438 and CPII16/ 00008
Références
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Diabetes. 2000 Apr;49(4):626-32
pubmed: 10871201
J Clin Endocrinol Metab. 2009 Sep;94(9):3530-4
pubmed: 19584183
Diabetes Metab Res Rev. 2020 Apr 7;:e3323
pubmed: 32266782
Clin Endocrinol (Oxf). 2005 Nov;63(5):525-9
pubmed: 16268804
Clin Chem Lab Med. 2006;44(11):1379-82
pubmed: 17087654
PLoS Med. 2012;9(10):e1001321
pubmed: 23055834
Med Sci Sports Exerc. 2004 Mar;36(3):556
pubmed: 15076800
Circulation. 1979 Jan;59(1):8-13
pubmed: 758126
Diabetologia. 2019 Jan;62(1):3-16
pubmed: 30171279
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Nat Rev Endocrinol. 2012 Apr 10;8(8):476-85
pubmed: 22488644
N Engl J Med. 2017 Apr 13;376(15):1407-1418
pubmed: 28402770
JAMA. 2015 Jan 6;313(1):37-44
pubmed: 25562264
Diabetes Care. 2006 Aug;29(8):1860-5
pubmed: 16873793
Diabetes Care. 2019 Jan;42(Suppl 1):S124-S138
pubmed: 30559237
Diabetes Res Clin Pract. 2010 Jun;88(3):314-21
pubmed: 20236721
J Diabetes Complications. 2016 May-Jun;30(4):586-90
pubmed: 26936306
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
J Clin Endocrinol Metab. 2016 Feb;101(2):686-95
pubmed: 26672636
Circulation. 2016 Mar 15;133(11):1058-66
pubmed: 26888765
Diabetologia. 2017 Oct;60(10):2084-2091
pubmed: 28711972
Diabetes Care. 2014 Oct;37(10):2843-63
pubmed: 25114297
Lancet. 2018 Aug 11;392(10146):477-486
pubmed: 30129464
N Engl J Med. 2014 Nov 20;371(21):1972-82
pubmed: 25409370
Diabet Med. 2011 Oct;28(10):1213-20
pubmed: 21627687
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetes Care. 2003 May;26(5):1374-9
pubmed: 12716791
Diabetologia. 2011 Jan;54(1):78-86
pubmed: 20886205
PLoS One. 2017 Apr 3;12(4):e0174640
pubmed: 28369151
PLoS One. 2019 Sep 4;14(9):e0220206
pubmed: 31483791
Diabetes Care. 2007 Mar;30(3):707-12
pubmed: 17327345
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Diabetes Care. 2017 Dec;40(12):1756-1762
pubmed: 29138273
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3814-3821
pubmed: 28938465
Clin Sci (Lond). 2001 Dec;101(6):671-9
pubmed: 11724655
Diabetes. 2003 Nov;52(11):2833-9
pubmed: 14578303